Patient characteristics
| Patient ID . | Treatment-naïve* . | Rai stage . | IGHV status† . | del(17p) . | CD38‡ . | CD49d‡ . | Decrease in adenopathy§ . |
|---|---|---|---|---|---|---|---|
| 01 | No | 1 | U | Yes | – | – | 72 |
| 02 | No | 3 | U | No | + | + | ND |
| 03 | No | 4 | U | Yes | + | + | 71 |
| 04 | No | 1 | M | No | – | + | 51 |
| 05 | No | 4 | U | Yes | – | + | 62 |
| 06 | No | 4 | M | No | + | + | 60 |
| 07 | Yes | 3 | U | Yes | + | – | 55 |
| 08 | No | 4 | U | No | – | + | 41 |
| 09 | Yes | 2 | U | Yes | – | – | 39 |
| 10 | No | 4 | M | Yes | + | – | 43 |
| 11 | Yes | 1 | U | Yes | – | – | 60 |
| 12 | No | 4 | U | No | + | – | 64 |
| 13 | No | 1 | U | No | + | – | 89 |
| 14 | No | 4 | U | No | + | + | 53 |
| 15 | No | 3 | U | No | + | – | 76 |
| 16 | Yes | 4 | U | Yes | – | – | 74 |
| 17 | No | 3 | U | Yes | – | + | 44 |
| 18 | Yes | 4 | M | Yes | – | – | 42 |
| 19 | No | 4 | U | Yes | + | + | 49 |
| 20 | Yes | 4 | M | No | – | – | 45 |
| 21 | Yes | 4 | M | Yes | – | + | 34 |
| 22 | Yes | 4 | M | No | + | + | 49 |
| 23 | No | 1 | M | Yes | + | – | 70 |
| – | Yes | 2 | M | Yes | – | – | 72 |
| 25 | No | 4 | M | No | + | + | 69 |
| 26 | Yes | 4 | U | No | – | – | 58 |
| 27 | Yes | 2 | M | No | – | + | 74 |
| 28 | Yes | 2 | M | No | – | – | 45 |
| 29 | No | 4 | U | Yes | – | + | 65 |
| 30 | No | 4 | M | Yes | – | + | 51 |
| 31 | Yes | 1 | M | Yes | – | – | 53 |
| 32 | No | 4 | M | No | + | + | 42 |
| 33 | No | 4 | U | Yes | + | + | 53 |
| 34 | No | 3 | U | No | – | + | 64 |
| 35 | No | 4 | M | Yes | – | + | 56 |
| 36 | No | 4 | U | No | + | + | 45 |
| Patient ID . | Treatment-naïve* . | Rai stage . | IGHV status† . | del(17p) . | CD38‡ . | CD49d‡ . | Decrease in adenopathy§ . |
|---|---|---|---|---|---|---|---|
| 01 | No | 1 | U | Yes | – | – | 72 |
| 02 | No | 3 | U | No | + | + | ND |
| 03 | No | 4 | U | Yes | + | + | 71 |
| 04 | No | 1 | M | No | – | + | 51 |
| 05 | No | 4 | U | Yes | – | + | 62 |
| 06 | No | 4 | M | No | + | + | 60 |
| 07 | Yes | 3 | U | Yes | + | – | 55 |
| 08 | No | 4 | U | No | – | + | 41 |
| 09 | Yes | 2 | U | Yes | – | – | 39 |
| 10 | No | 4 | M | Yes | + | – | 43 |
| 11 | Yes | 1 | U | Yes | – | – | 60 |
| 12 | No | 4 | U | No | + | – | 64 |
| 13 | No | 1 | U | No | + | – | 89 |
| 14 | No | 4 | U | No | + | + | 53 |
| 15 | No | 3 | U | No | + | – | 76 |
| 16 | Yes | 4 | U | Yes | – | – | 74 |
| 17 | No | 3 | U | Yes | – | + | 44 |
| 18 | Yes | 4 | M | Yes | – | – | 42 |
| 19 | No | 4 | U | Yes | + | + | 49 |
| 20 | Yes | 4 | M | No | – | – | 45 |
| 21 | Yes | 4 | M | Yes | – | + | 34 |
| 22 | Yes | 4 | M | No | + | + | 49 |
| 23 | No | 1 | M | Yes | + | – | 70 |
| – | Yes | 2 | M | Yes | – | – | 72 |
| 25 | No | 4 | M | No | + | + | 69 |
| 26 | Yes | 4 | U | No | – | – | 58 |
| 27 | Yes | 2 | M | No | – | + | 74 |
| 28 | Yes | 2 | M | No | – | – | 45 |
| 29 | No | 4 | U | Yes | – | + | 65 |
| 30 | No | 4 | M | Yes | – | + | 51 |
| 31 | Yes | 1 | M | Yes | – | – | 53 |
| 32 | No | 4 | M | No | + | + | 42 |
| 33 | No | 4 | U | Yes | + | + | 53 |
| 34 | No | 3 | U | No | – | + | 64 |
| 35 | No | 4 | M | Yes | – | + | 56 |
| 36 | No | 4 | U | No | + | + | 45 |
Among the 13 relapsed patients, the median number of prior treatments was 3 with a range of 1-7.
Unmutated indicates <2% change in IGHV gene sequence compared with germline.
CD38 or CD49d positive (+) indicates ≥30% of CLL cells express surface antigen above isotype control.
Decrease in lymphadenopathy was determined by the percent reduction in the sum of the product of the diameters of up to 4 lymph nodes on CT scan after 2 cycles compared with baseline. A nodal response is defined as >50% reduction. Samples that were not determined are indicated by ND.